KRAS and non-small cell lung carcinoma: In the current study, we compared abemaciclib to erlotinib, both in combination with best supportive care, in patients with stage IV NSCLC who had KRAS-mutated tumors and had progressed after platinum-based chemotherapy plus one other anti-cancer therapy.